Claim and evidence Close ×
Insilico Medicine announced on 8 July 2026 that rentosertib (ISM001-055), which it states it discovered and developed, had entered a Phase III clinical trial registered as CTR20262475 and NCT07687459. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Provision Statement · provision ID co-insilico-rentosertib-phase3-initiation-2026 Date 2026-07-08 · publication Records dated 2026 → Scope and limits The company's statement; the registry entries it names are separate sources, not retrieved. The announcement describes rentosertib as "discovered and developed with the support of" its generative AI platform; that characterisation is the company's.
The evidence 02 primary source Supports the claim
InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial ↗ InSilico Medicine Cayman TopCo, published on HKEXnews · 2026-07-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Rentosertib (ISM001-055), independently discovered and developed by Insilico Medicine, has officially entered Phase III clinical trial (CTR20262475, NCT07687459)” Location in source first paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors InSilico Medicine Cayman TopCo, published on HKEXnews Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 f3885577b28b14e540aa411ce2227da6bc3702b2bdfd64eb1c9c3beb41239c69). HKEXnews PDF 2026070800129, listed 2026-07-08, as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution InSilico Medicine Cayman TopCo, published on HKEXnews, “InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial”, 2026-07-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (18 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial ↗ InSilico Medicine Cayman TopCo, published on HKEXnews · 2026-07-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “discovered and developed with the support of Insilico Medicine’s proprietary generative AI platform, Pharma. AI.” Location in source About Rentosertib
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors InSilico Medicine Cayman TopCo, published on HKEXnews Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 f3885577b28b14e540aa411ce2227da6bc3702b2bdfd64eb1c9c3beb41239c69). HKEXnews PDF 2026070800129, listed 2026-07-08, as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution InSilico Medicine Cayman TopCo, published on HKEXnews, “InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial”, 2026-07-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (15 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.
Date. Date of the HKEXnews listing of the announcement. The record is dated by the text’s date of publication, which is the date of its announcement.
Record ID aib-co-insilico-rentosertib-phase3-initiation-2026